T

TARS

TARS

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
0%Bearish
Buy/Sell Ratio0% buys
BearishBullish
TARS Live QuoteReal-time
$73.01
+$0.93(+1.29%)1M
Day Range$72.74 – $78.11
Open$77.09
Previous Close$77.67
Volume706.8K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$3.83B
P/E Ratio (TTM)24.5
Forward P/E62.9
EPS (TTM)$-15.86
Price to Book36.0
Dividend Yield0.65%
Beta (Volatility)0.33
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $73.01 (51%)
Low: $53.89High: $91.53
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$103.44-31.0% upside

Insider Buys

0

$0

Insider Sales

37

$25.89M

Total Volume

$25.89M

37 transactions

Net Activity

$25.89M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
15CONFIDENCE

Sentiment Rating

Heavy Distribution

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Heavy distribution: sales represent 100% of total transaction value.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
  • •Significant liquidation: total sale value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
A
1

Azamian Bobak R.

Pres, CEO, Board Chair

0 buys9 sells

$7.28M total

L
2

Link William J Phd

Dir

0 buys5 sells

$6.03M total

W
3

Whitfield Dianne C.

CHRO

0 buys4 sells

$3.01M total

N
4

Neervannan Seshadri

COO

0 buys5 sells

$2.36M total

M
5

Mottiwala Aziz

Chief Commercial Officer

0 buys3 sells

$2.16M total

Trading History
TARS insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Sep 15, 2026

2 months ago

Link William J Phd

Dir

Director
Sell12.5K$78.38$980K

Sep 4, 2026

2 months ago

Azamian Bobak R.

Pres, CEO, Board Chair

CEO
Sell10.0K$90.56$906K

Sep 4, 2026

2 months ago

Lin Elizabeth Yeu

Chief Medical Officer

C-Level
Sell14.0K$87.50$1.22M

Sep 4, 2026

2 months ago

Neervannan Seshadri

COO

COO
Sell4.6K$85.00$388K

Sep 2, 2026

2 months ago

Azamian Bobak R.

Pres, CEO, Board Chair

CEO
Sell10.0K$80.06$801K

Jun 17, 2026

5 months ago

Azamian Bobak R.

Pres, CEO, Board Chair

CEO
Sell10.0K$61.55$615K

Jun 16, 2026

5 months ago

Farrow Jeffrey S

See Remarks

Insider
Sell14.4K$60.95$877K

Jun 15, 2026

5 months ago

Goodrich Katherine

Dir

Director
Sell3.0K$62.08$183K

Jun 15, 2026

5 months ago

Link William J Phd

Dir

Director
Sell12.5K$62.12$776K

Mar 20, 2026

8 months ago

Neervannan Seshadri

COO

COO
Sell3.0K$66.75$200K

Mar 17, 2026

8 months ago

Whitfield Dianne C.

CHRO

C-Level
Sell12.3K$68.36$839K

Mar 17, 2026

8 months ago

Wahl Bryan

GC

General Counsel
Sell12.4K$68.36$850K

Mar 17, 2026

8 months ago

Neervannan Seshadri

COO

COO
Sell11.3K$68.21$772K

Mar 17, 2026

8 months ago

Mottiwala Aziz

Chief Commercial Officer

C-Level
Sell13.1K$68.36$893K

Mar 17, 2026

8 months ago

Lin Elizabeth Yeu

Chief Medical Officer

C-Level
Sell1.1K$68.36$78K

Mar 17, 2026

8 months ago

Farrow Jeffrey S

See Remarks

Insider
Sell6.4K$68.36$440K

Mar 17, 2026

8 months ago

Azamian Bobak R.

Pres, CEO, Board Chair

CEO
Sell34.6K$68.34$2.36M

Mar 16, 2026

8 months ago

Link William J Phd

Dir

Director
Sell12.5K$68.79$860K

Mar 4, 2026

8 months ago

Neervannan Seshadri

COO

COO
Sell8.4K$76.67$641K

Jan 2, 2026

10 months ago

Whitfield Dianne C.

CHRO

C-Level
Sell15.6K$80.67$1.26M

Dec 24, 2025

11 months ago

Azamian Bobak R.

Pres, CEO, Board Chair

CEO
Sell6.0K$82.51$495K

Dec 16, 2025

11 months ago

Whitfield Dianne C.

CHRO

C-Level
Sell7.4K$80.10$593K

Dec 15, 2025

11 months ago

Link William J Phd

Dir

Director
Sell22.9K$81.26$1.86M

Dec 16, 2025

11 months ago

Lin Elizabeth Yeu

Chief Medical Officer

C-Level
Sell2.1K$79.50$165K

Sep 24, 2025

14 months ago

Azamian Bobak R.

Pres, CEO, Board Chair

CEO
Sell6.0K$55.37$332K

Sep 8, 2025

14 months ago

Link William J Phd

Dir

Director
Sell27.1K$57.00$1.55M

Aug 11, 2025

15 months ago

Azamian Bobak R.

Pres, CEO, Board Chair

CEO
Sell6.0K$50.00$300K

Jun 17, 2025

17 months ago

Farrow Jeffrey S

See Remarks

Insider
Sell13.6K$40.42$550K

Jun 16, 2025

17 months ago

Lin Elizabeth Yeu

Chief Medical Officer

C-Level
Sell1.0K$41.08$41K

Jun 9, 2025

17 months ago

Mottiwala Aziz

Chief Commercial Officer

C-Level
Sell17.5K$43.76$766K

Mar 24, 2025

20 months ago

Azamian Bobak R.

Pres, CEO, Board Chair

CEO
Sell6.0K$50.00$300K

Mar 18, 2025

20 months ago

Mottiwala Aziz

Chief Commercial Officer

C-Level
Sell10.6K$47.88$506K

Mar 18, 2025

20 months ago

Neervannan Seshadri

COO

COO
Sell7.6K$47.89$363K

Mar 18, 2025

20 months ago

Wahl Bryan

GC

General Counsel
Sell9.7K$47.88$464K

Mar 18, 2025

20 months ago

Whitfield Dianne C.

CHRO

C-Level
Sell6.7K$47.88$321K

Mar 18, 2025

20 months ago

Azamian Bobak R.

Pres, CEO, Board Chair

CEO
Sell24.2K$48.03$1.16M

Mar 18, 2025

20 months ago

Farrow Jeffrey S

See Remarks

Insider
Sell3.7K$47.88$178K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
TARS Buy Conviction0%
Industry Rank#0 of 569
Volume Contribution0.2%
Total Industry Activity$16.52B

TARS has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for TARS

Over the last 90 days, corporate insiders at TARS (TARS) engaged in a total of 37 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 37 were sales. The total volume of insider trading reached $25.89M.

The net insider activity for TARS shows a net selling bias of $25.89M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Azamian Bobak R. (Pres, CEO, Board Chair), who traded 34.6K shares valued at $2.36M on Mar 17, 2026.

Live Market News & Developments
Aggregated real-time headlines for TARS (TARS)
6 updates

Tarsus Pharmaceuticals (TARS) Stock Looks Cheap On Its 342% Run

Yahoo Finance13h ago

6 Green Days In A Row: Tarsus Pharmaceuticals Stock Is Up 19%

Trefis6d ago

Tarsus plans two investor talks, in November and December

Stock Titan15d ago

Tarsus Pharmaceuticals (TARS) Stock May Trade At A Discount On Strong Sales Growth

Simply Wall St14d ago

Tarsus: Not Cheap, But Xdemvy Makes The Valuation Work

Seeking Alpha154d ago

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme

Yahoo Finance142d ago

FAQs About TARS Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for TARS.

Based on SEC Form 4 disclosures, the Insider Confidence Score for TARS is currently 15/100, which reflects a heavy distribution bias. This calculation accounts for a total of 0 purchases and 37 sales by company executives over the last 90 days.

The CEO Conviction Index for TARS is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.